Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence
Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2012-05, Vol.21 (5), p.720-727 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 727 |
|---|---|
| container_issue | 5 |
| container_start_page | 720 |
| container_title | Cancer epidemiology, biomarkers & prevention |
| container_volume | 21 |
| creator | BUIST, Diana S. M WALKER, Rod BOWLES, Erin J. Aiello CARNEY, Patricia A TAPLIN, Stephen H ONEGA, Tracy KERLIKOWSKE, Karla CLINTON, Walter MIGLIORETTI, Diana L |
| description | Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)].
We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no).
Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group.
Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression.
Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency. |
| doi_str_mv | 10.1158/1055-9965.EPI-11-1115 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3348383</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1011851269</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-75145cfc0bf2cb1bb127b9f4e94117f05a84be695fc03bae40d7636e18eb16c33</originalsourceid><addsrcrecordid>eNpVkV9vFCEUxYnR2D_6ETS8mPjQqdxhmGFeTOq6tZvUarR9JsDe2cXMwAqzTfcz-KVl7LZqQgI5_M7hhkPIK2CnAEK-AyZE0ba1OJ1_XRQAeYF4Qg5BcFk0jRBP8_mBOSBHKf1gjDWtEM_JQVlyBpLDIfn13UZE7_yKftbDEFZRb9Y7epOQ6iFkdbaNEf14Qs9DHDCeUO2X9ApvMdKLrASP9HqN2fXHFFOO2dGrMNL53abXztNvaLOffkTbO4-JZulDRJ1GOtPe5piFt26J-fiCPOt0n_Dlfj8mN-fz69lFcfnl02J2dlnYqoKxaARUwnaWma60BoyBsjFtV2FbATQdE1pWButWZIQbjRVbNjWvESQaqC3nx-T9fe5mawZcTuNF3atNdIOOOxW0U__feLdWq3CrOK8kl1PA231ADD-3mEY1uGSx77XHsE0KGIAUUNZtRsU9amNIKWL3-AwwNRWpppLUVJLKRWZJTUVm3-t_Z3x0PTSXgTd7QCer-y7mz3TpLydk3ZQ56DfD3qi9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1011851269</pqid></control><display><type>article</type><title>Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>BUIST, Diana S. M ; WALKER, Rod ; BOWLES, Erin J. Aiello ; CARNEY, Patricia A ; TAPLIN, Stephen H ; ONEGA, Tracy ; KERLIKOWSKE, Karla ; CLINTON, Walter ; MIGLIORETTI, Diana L</creator><creatorcontrib>BUIST, Diana S. M ; WALKER, Rod ; BOWLES, Erin J. Aiello ; CARNEY, Patricia A ; TAPLIN, Stephen H ; ONEGA, Tracy ; KERLIKOWSKE, Karla ; CLINTON, Walter ; MIGLIORETTI, Diana L</creatorcontrib><description>Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)].
We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no).
Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group.
Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression.
Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-11-1115</identifier><identifier>PMID: 22301831</identifier><identifier>CODEN: CEBPE4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Aged ; Biological and medical sciences ; Breast Neoplasms - diagnostic imaging ; Breast Neoplasms - epidemiology ; Breast Neoplasms - prevention & control ; Carcinoma, Intraductal, Noninfiltrating - diagnostic imaging ; Carcinoma, Intraductal, Noninfiltrating - epidemiology ; Cohort Studies ; Early Detection of Cancer - methods ; Early Detection of Cancer - statistics & numerical data ; Female ; Gynecology. Andrology. Obstetrics ; Hormone Replacement Therapy - statistics & numerical data ; Humans ; Incidence ; Longitudinal Studies ; Mammary gland diseases ; Mammography - methods ; Mammography - statistics & numerical data ; Mammography - utilization ; Mass Screening ; Medical sciences ; Middle Aged ; SEER Program ; Tumors ; Washington - epidemiology</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2012-05, Vol.21 (5), p.720-727</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-75145cfc0bf2cb1bb127b9f4e94117f05a84be695fc03bae40d7636e18eb16c33</citedby><cites>FETCH-LOGICAL-c441t-75145cfc0bf2cb1bb127b9f4e94117f05a84be695fc03bae40d7636e18eb16c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25867215$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22301831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BUIST, Diana S. M</creatorcontrib><creatorcontrib>WALKER, Rod</creatorcontrib><creatorcontrib>BOWLES, Erin J. Aiello</creatorcontrib><creatorcontrib>CARNEY, Patricia A</creatorcontrib><creatorcontrib>TAPLIN, Stephen H</creatorcontrib><creatorcontrib>ONEGA, Tracy</creatorcontrib><creatorcontrib>KERLIKOWSKE, Karla</creatorcontrib><creatorcontrib>CLINTON, Walter</creatorcontrib><creatorcontrib>MIGLIORETTI, Diana L</creatorcontrib><title>Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)].
We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no).
Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group.
Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression.
Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - diagnostic imaging</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Carcinoma, Intraductal, Noninfiltrating - diagnostic imaging</subject><subject>Carcinoma, Intraductal, Noninfiltrating - epidemiology</subject><subject>Cohort Studies</subject><subject>Early Detection of Cancer - methods</subject><subject>Early Detection of Cancer - statistics & numerical data</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hormone Replacement Therapy - statistics & numerical data</subject><subject>Humans</subject><subject>Incidence</subject><subject>Longitudinal Studies</subject><subject>Mammary gland diseases</subject><subject>Mammography - methods</subject><subject>Mammography - statistics & numerical data</subject><subject>Mammography - utilization</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>SEER Program</subject><subject>Tumors</subject><subject>Washington - epidemiology</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV9vFCEUxYnR2D_6ETS8mPjQqdxhmGFeTOq6tZvUarR9JsDe2cXMwAqzTfcz-KVl7LZqQgI5_M7hhkPIK2CnAEK-AyZE0ba1OJ1_XRQAeYF4Qg5BcFk0jRBP8_mBOSBHKf1gjDWtEM_JQVlyBpLDIfn13UZE7_yKftbDEFZRb9Y7epOQ6iFkdbaNEf14Qs9DHDCeUO2X9ApvMdKLrASP9HqN2fXHFFOO2dGrMNL53abXztNvaLOffkTbO4-JZulDRJ1GOtPe5piFt26J-fiCPOt0n_Dlfj8mN-fz69lFcfnl02J2dlnYqoKxaARUwnaWma60BoyBsjFtV2FbATQdE1pWButWZIQbjRVbNjWvESQaqC3nx-T9fe5mawZcTuNF3atNdIOOOxW0U__feLdWq3CrOK8kl1PA231ADD-3mEY1uGSx77XHsE0KGIAUUNZtRsU9amNIKWL3-AwwNRWpppLUVJLKRWZJTUVm3-t_Z3x0PTSXgTd7QCer-y7mz3TpLydk3ZQ56DfD3qi9</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>BUIST, Diana S. M</creator><creator>WALKER, Rod</creator><creator>BOWLES, Erin J. Aiello</creator><creator>CARNEY, Patricia A</creator><creator>TAPLIN, Stephen H</creator><creator>ONEGA, Tracy</creator><creator>KERLIKOWSKE, Karla</creator><creator>CLINTON, Walter</creator><creator>MIGLIORETTI, Diana L</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120501</creationdate><title>Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence</title><author>BUIST, Diana S. M ; WALKER, Rod ; BOWLES, Erin J. Aiello ; CARNEY, Patricia A ; TAPLIN, Stephen H ; ONEGA, Tracy ; KERLIKOWSKE, Karla ; CLINTON, Walter ; MIGLIORETTI, Diana L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-75145cfc0bf2cb1bb127b9f4e94117f05a84be695fc03bae40d7636e18eb16c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - diagnostic imaging</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Carcinoma, Intraductal, Noninfiltrating - diagnostic imaging</topic><topic>Carcinoma, Intraductal, Noninfiltrating - epidemiology</topic><topic>Cohort Studies</topic><topic>Early Detection of Cancer - methods</topic><topic>Early Detection of Cancer - statistics & numerical data</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hormone Replacement Therapy - statistics & numerical data</topic><topic>Humans</topic><topic>Incidence</topic><topic>Longitudinal Studies</topic><topic>Mammary gland diseases</topic><topic>Mammography - methods</topic><topic>Mammography - statistics & numerical data</topic><topic>Mammography - utilization</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>SEER Program</topic><topic>Tumors</topic><topic>Washington - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BUIST, Diana S. M</creatorcontrib><creatorcontrib>WALKER, Rod</creatorcontrib><creatorcontrib>BOWLES, Erin J. Aiello</creatorcontrib><creatorcontrib>CARNEY, Patricia A</creatorcontrib><creatorcontrib>TAPLIN, Stephen H</creatorcontrib><creatorcontrib>ONEGA, Tracy</creatorcontrib><creatorcontrib>KERLIKOWSKE, Karla</creatorcontrib><creatorcontrib>CLINTON, Walter</creatorcontrib><creatorcontrib>MIGLIORETTI, Diana L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BUIST, Diana S. M</au><au>WALKER, Rod</au><au>BOWLES, Erin J. Aiello</au><au>CARNEY, Patricia A</au><au>TAPLIN, Stephen H</au><au>ONEGA, Tracy</au><au>KERLIKOWSKE, Karla</au><au>CLINTON, Walter</au><au>MIGLIORETTI, Diana L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>21</volume><issue>5</issue><spage>720</spage><epage>727</epage><pages>720-727</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><coden>CEBPE4</coden><abstract>Screening mammography and invasive breast cancer and ductal carcinoma in situ (DCIS) rates recently declined in the United States; screening mammography declines among former hormone therapy (HT) users may be an important contributor. We longitudinally examined women and compared mammography use and cancer rates by HT use [current, former, and never users of estrogen + progestin (EPT) and estrogen only (ET)].
We studied 163,490 unique women aged 50-79 years enrolled in Group Health (Washington State) between 1994-2009. Electronic data identified HT dispensing, mammography use and incident breast cancer diagnosis. We calculated age-adjusted screening compliance as a time-varying variable (screened-within-the-past-26 months, yes/no).
Before 2002, screening compliance differed significantly by HT with current EPT users having the highest rates (83%) followed by former EPT (77%), current ET (77%), former ET (72%), and never users (56%). After 2002, screening was high (∼81%) among current and former EPT and ET users and significantly increased among never users (∼62%). Invasive breast cancer rates significantly decreased over the whole study period (P(trend) ≤ 0.05) for all HT users, except EPT current users (P(trend) = 0.68); DCIS rates did not change in any group.
Differential screening mammography rates by HT use do not explain invasive breast cancer incidence declines. Our data suggest discontinuing HT has an immediate effect on breast cancer rates, lending support to the mechanism that cessation leads to tumor regression.
Studies examining the influence of a changing exposure in relation to outcomes should account for varying exposures, individuals' characteristics, as well as screening methods and frequency.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>22301831</pmid><doi>10.1158/1055-9965.EPI-11-1115</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1055-9965 |
| ispartof | Cancer epidemiology, biomarkers & prevention, 2012-05, Vol.21 (5), p.720-727 |
| issn | 1055-9965 1538-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3348383 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Biological and medical sciences Breast Neoplasms - diagnostic imaging Breast Neoplasms - epidemiology Breast Neoplasms - prevention & control Carcinoma, Intraductal, Noninfiltrating - diagnostic imaging Carcinoma, Intraductal, Noninfiltrating - epidemiology Cohort Studies Early Detection of Cancer - methods Early Detection of Cancer - statistics & numerical data Female Gynecology. Andrology. Obstetrics Hormone Replacement Therapy - statistics & numerical data Humans Incidence Longitudinal Studies Mammary gland diseases Mammography - methods Mammography - statistics & numerical data Mammography - utilization Mass Screening Medical sciences Middle Aged SEER Program Tumors Washington - epidemiology |
| title | Screening Mammography Use among Current, Former, and Never Hormone Therapy Users May Not Explain Recent Declines in Breast Cancer Incidence |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T03%3A56%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening%20Mammography%20Use%20among%20Current,%20Former,%20and%20Never%20Hormone%20Therapy%20Users%20May%20Not%20Explain%20Recent%20Declines%20in%20Breast%20Cancer%20Incidence&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=BUIST,%20Diana%20S.%20M&rft.date=2012-05-01&rft.volume=21&rft.issue=5&rft.spage=720&rft.epage=727&rft.pages=720-727&rft.issn=1055-9965&rft.eissn=1538-7755&rft.coden=CEBPE4&rft_id=info:doi/10.1158/1055-9965.EPI-11-1115&rft_dat=%3Cproquest_pubme%3E1011851269%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1011851269&rft_id=info:pmid/22301831&rfr_iscdi=true |